Gilead Files For Remdesivir Approval In EU

A Decision Could Be Made In Weeks

The much-anticipated EU filing for Gilead’s COVID-19 treatment is being reviewed quickly by the European Medicines Agency.

Banja Luka, Bosnia and Herzegovina, 18.3.2020. Concept of medical bottle with new possible cure for Coronavirus COVID 19. Remdesivir therapy for Korona virus medication potential drug
Remdesivir is already in use in COVID-19 in several major markets • Source: Shutterstock

Gilead Sciences has filed for conditional approval in the EU of its investigational antiviral drug, remdesivir, for treating COVID-19. The review could be completed in weeks.

The European Medicines Agency announced today that it had received the application and said that its decision on whether to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>